Spero Therapeutics
Multi-Asset, clinical-stage biopharmaceutical company focused on multidrug-resistant bacterial infections.
Launch date
Employees
Market cap
AUD114m
Enterprise valuation
AUD24m (Public information from Sep 2024)
Share price
$1.34 SPRO
Cambridge Massachusetts (HQ)
Authorizing premium user...